Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Consolidated Net Income (2020 - 2023)

Historic Consolidated Net Income for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.5 million.

  • Immuneering's Consolidated Net Income fell 1543.57% to -$15.5 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$15.5 million, marking a year-over-year increase of 7051.25%. This contributed to the annual value of -$54.8 million for FY2023, which is 849.74% down from last year.
  • Latest data reveals that Immuneering reported Consolidated Net Income of -$15.5 million as of Q4 2023, which was down 1543.57% from -$13.1 million recorded in Q3 2023.
  • Immuneering's 5-year Consolidated Net Income high stood at -$3.6 million for Q2 2020, and its period low was -$15.5 million during Q4 2023.
  • In the last 4 years, Immuneering's Consolidated Net Income had a median value of -$11.5 million in 2022 and averaged -$10.2 million.
  • Per our database at Business Quant, Immuneering's Consolidated Net Income tumbled by 12162.34% in 2021 and then tumbled by 81.48% in 2023.
  • Over the past 4 years, Immuneering's Consolidated Net Income (Quarter) stood at -$5.8 million in 2020, then crashed by 88.02% to -$11.0 million in 2021, then decreased by 22.75% to -$13.5 million in 2022, then dropped by 15.44% to -$15.5 million in 2023.
  • Its Consolidated Net Income was -$15.5 million in Q4 2023, compared to -$13.1 million in Q3 2023 and -$12.3 million in Q2 2023.